As Goes Biogen So Follows The Biotech Industry

As Goes Biogen So Follows The Biotech Industry


The catalyst for the newfound enthusiasm is data presented on Biogen's lead compound Aducanumab for the treatment of Alzheimer's disease. Biogen continues its streak of market moving events in the biotech space for 2016.



from Biotech News